FDA Highlights Safety Protocols for Hyperbaric Oxygen Therapy Devices

The U.S. Food and Drug Administration (FDA) has issued important warnings to healthcare providers regarding the proper and safe use of hyperbaric oxygen therapy (HBOT) devices. These devices utilize pressurized chambers to deliver 100% oxygen, which enhances oxygen absorption in the lungs, thereby aiding healing processes and combating infections.

Recently, the FDA has received reports of fires linked to HBOT devices, leading to severe injuries and fatalities. Though such incidents are uncommon, they emphasize the critical need for strict adherence to manufacturer guidelines to mitigate risks. Healthcare professionals are advised to implement comprehensive fire prevention measures, including proper grounding of equipment.

Staff working with HBOT must undergo ongoing training to understand the heightened fire risks associated with high oxygen concentrations. During treatments, patients should be continuously monitored, and their clothing should comply with manufacturer recommendations—preferably natural fibers like cotton—as synthetic or wool fabrics can generate static electricity, increasing fire hazards. Additionally, all prohibited items such as electrical or static-generating devices should be avoided in the treatment area.

Facilities are instructed to follow prescribed cleaning, maintenance, and safety check protocols for each device to ensure optimal safety. The FDA plans to collaborate with device manufacturers and professional societies to promote comprehensive training programs and standardized safety procedures. Healthcare providers are also encouraged to report any adverse events or safety concerns related to HBOT devices.

Adhering to these safety protocols is vital for the safe and effective use of hyperbaric oxygen therapy, underscoring the importance of ongoing vigilance, proper staff training, and patient monitoring to prevent tragic incidents.

For more information, visit FDA Hyperbaric Oxygen Therapy Safety Guide.